CLDN10 Associated with Immune Infiltration is a Novel Prognostic Biomarker for Clear Cell Renal Cell Carcinoma

References

• Siegel RL , MillerKD , JemalA. Cancer statistics, 2020. CA Cancer J Clin.70(1), 7–30 (2020).
   PubMed Web of Science ®Google Scholar
• Hsieh JJ , PurdueMP , SignorettiSet al. Renal cell carcinoma. Nat. Rev. Dis. Primers3, 17009 (2017).
   PubMed Web of Science ®Google Scholar
• Moch H , CubillaAL , HumphreyPAet al. The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur. Urol.70(1), 93–105 (2016).
   PubMed Web of Science ®Google Scholar
• Patard JJ , PignotG , EscudierBet al. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur. Urol.60(4), 684–690 (2011).
   PubMed Web of Science ®Google Scholar
• Capitanio U , MontorsiF. Renal cancer. Lancet387(10021), 894–906 (2016).
   PubMed Web of Science ®Google Scholar
• Rini BI , CampbellSC , EscudierB. Renal cell carcinoma. Lancet373(9669), 1119–1132 (2009).
   PubMed Web of Science ®Google Scholar
• Janzen NK , KimHL , FiglinRA , BelldegrunAS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North Am.30(4), 843–852 (2003).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , MotzerRJ. Systemic therapy for metastatic renal-cell carcinoma. New Engl. J. Med.376(4), 354–366 (2017).
   PubMed Web of Science ®Google Scholar
• Hirohashi S , KanaiY. Cell adhesion system and human cancer morphogenesis. Cancer Sci.94(7), 575–581 (2003).
   PubMed Web of Science ®Google Scholar
• Tsukita S , FuruseM , ItohM. Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol.2(4), 285–293 (2001).
   PubMed Web of Science ®Google Scholar
• Huang GW , DingX , ChenSL , ZengL. Expression of claudin 10 protein in hepatocellular carcinoma: Impact on survival. J. Cancer Res. Clin. Oncol.137(8), 1213–1218 (2011).
   PubMed Web of Science ®Google Scholar
• Zhou Y , XiangJ , BhandariAet al. CLDN10 is associated with papillary thyroid cancer progression. J. Cancer9(24), 4712–4717 (2018).
   PubMed Web of Science ®Google Scholar
• Yang W , ZhangK , LiLet al. Discovery and validation of the prognostic value of the lncRNAs encoding snoRNAs in patients with clear cell renal cell carcinoma. Aging12(5), 4424–4444 (2020).
   PubMedGoogle Scholar
• Şenbabaoğlu Y , GejmanRS , WinerAGet al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology17(1), 231 (2016).
   PubMed Web of Science ®Google Scholar
• Yoshihara K , ShahmoradgoliM , MartinezEet al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun.4, 2612 (2013).
   PubMed Web of Science ®Google Scholar
• Thompson RH , DongH , LohseCMet al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res.13(6), 1757–1761 (2007).
   PubMed Web of Science ®Google Scholar
• Xiang Z , ZhongC , ChangAet al. Immune-related key gene CLDN10 correlates with lymph node metastasis but predicts favorable prognosis in papillary thyroid carcinoma. Aging12(3), 2825–2839 (2020).
   PubMedGoogle Scholar
• Xu L , DengC , PangBet al. TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res.78(23), 6575–6580 (2018).
   PubMed Web of Science ®Google Scholar
• Swisshelm K , MacekR , KubbiesM. Role of claudins in tumorigenesis. Adv. Drug Delivery Rev.57(6), 919–928 (2005).
   PubMed Web of Science ®Google Scholar
• Kominsky SL . Claudins: emerging targets for cancer therapy. Exp. Rev. Mol. Med.8(18), 1–11 (2006).
   PubMedGoogle Scholar
• Luo Y , KishiS , SasakiTet al. Targeting claudin-4 enhances chemosensitivity in breast cancer. Cancer Sci.111(5), 1840–1850 (2020).
   PubMed Web of Science ®Google Scholar
• Cherradi S , Ayrolles-TorroA , Vezzo-VieNet al. Antibody targeting of claudin-1 as a potential colorectal cancer therapy. J. Exp. Clin. Cancer Res.36(1), 89 (2017).
   PubMedGoogle Scholar
• Singh P , ToomS , HuangY. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J. Hematol. Oncol.10(1), 105 (2017).
   PubMedGoogle Scholar
• Gao Y , LiuX , LiTet al. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncol. Rep.37(5), 3084–3092 (2017).
   PubMed Web of Science ®Google Scholar
• Li Y , GongY , NingXet al. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis. J. Exp. Clin. Cancer Res.37(1), 276 (2018).
   PubMedGoogle Scholar
• Kwon MJ . Emerging roles of claudins in human cancer. Int. J. Mol. Sci.14(9), 18148–18180 (2013).
   PubMed Web of Science ®Google Scholar
• Honda H , PazinMJ , JiHet al. Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J. Biol. Chem.281(30), 21433–21444 (2006).
   PubMed Web of Science ®Google Scholar
• Sahin U , KoslowskiM , DhaeneKet al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res.14(23), 7624–7634 (2008).
   PubMed Web of Science ®Google Scholar
• Ito T , KojimaT , YamaguchiHet al. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. J. Cell. Biochem.112(7), 1761–1772 (2011).
   PubMed Web of Science ®Google Scholar
• Liu S , LiS , WangYet al. Prognostic value of infiltrating immune cells in clear cell renal cell carcinoma (ccRCC). J. Cell. Biochem.121(3), 2571–2581 (2020).
   PubMed Web of Science ®Google Scholar